- Home
- KIDS vs SIGA Comparison
KIDS vs SIGA Comparison
Compare KIDS & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | SIGA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.9M | 486.2M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KIDS | SIGA |
|---|---|---|
| Price | $17.60 | $5.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $24.67 | N/A |
| AVG Volume (30 Days) | 114.8K | ★ 395.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.35% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | $132.36 |
| P/E Ratio | ★ N/A | $14.48 |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $15.34 | $4.95 |
| 52 Week High | $26.40 | $9.62 |
Technical Indicators
Market Signals| Indicator | KIDS | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 31.13 |
| Support Level | $17.62 | $5.21 |
| Resistance Level | $19.36 | $6.98 |
| Average True Range (ATR) | 1.02 | 0.25 |
| MACD | 0.10 | -0.13 |
| Stochastic Oscillator | 44.85 | 20.58 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.